Despite the global administration of approved COVID-19 vaccines(e.g.,ChAdOx1 nCoV-19?,mRNA-1273?,BNT162b2?),the number of infections and fatalities continue to rise at an alarming rate because of the new variants such...Despite the global administration of approved COVID-19 vaccines(e.g.,ChAdOx1 nCoV-19?,mRNA-1273?,BNT162b2?),the number of infections and fatalities continue to rise at an alarming rate because of the new variants such as Omicron and its subvariants.Including COVID-19 vaccines that are licensed for human use,most of the vaccines that are currently in clinical trials are administered via parenteral route.However,it has been proven that the parenteral vaccines do not induce localized immunity in the upper respiratory mucosal surface,and administration of the currently approved vaccines does not necessarily lead to sterilizing immunity.This further supports the necessity of a mucosal vaccine that blocks the main entrance route of COVID-19:nasal and oral mucosal surfaces.Understanding the mechanism of immune regulation of M cells and dendritic cells and targeting them can be another promising approach for the successful stimulation of the mucosal immune system.This paper reviews the basic mechanisms of the mucosal immunity elicited by mucosal vaccines and summarizes the practical aspects and challenges of nanotechnology-based vaccine platform development,as well as ligand hybrid nanoparticles as potentially effective target delivery agents for mucosal vaccines.展开更多
Orally administered drug entities have to survive the harsh gastrointestinal environment,penetrate the enteric epithelia and circumvent hepatic metabolism before reaching the systemic circulation.Whereas the gastroint...Orally administered drug entities have to survive the harsh gastrointestinal environment,penetrate the enteric epithelia and circumvent hepatic metabolism before reaching the systemic circulation.Whereas the gastrointestinal stability can be well maintained by taking proper measures,hepatic metabolism presents as a formidable barrier to drugs suffering from first-pass metabolism.The pharmaceutical academia and industries are seeking alternative pathways for drug transport to circumvent problems associated with the portal pathway.Intestinal lymphatic transport is emerging as a promising pathway to this end.In this review,we intend to provide an updated overview on the rationale,strategies,factors and applications involved in intestinal lymphatic transport.There are mainly two pathways for peroral lymphatic transportdthe chylomicron and the microfold cell pathways.The underlying mechanisms are being unraveled gradually and nowadays witness increasing research input and applications.展开更多
基金supported by grants from the National Research Foundation of Korea(2019R1A2C1085986,2022M3A9H1014123,2022M3A9G8018189)。
文摘Despite the global administration of approved COVID-19 vaccines(e.g.,ChAdOx1 nCoV-19?,mRNA-1273?,BNT162b2?),the number of infections and fatalities continue to rise at an alarming rate because of the new variants such as Omicron and its subvariants.Including COVID-19 vaccines that are licensed for human use,most of the vaccines that are currently in clinical trials are administered via parenteral route.However,it has been proven that the parenteral vaccines do not induce localized immunity in the upper respiratory mucosal surface,and administration of the currently approved vaccines does not necessarily lead to sterilizing immunity.This further supports the necessity of a mucosal vaccine that blocks the main entrance route of COVID-19:nasal and oral mucosal surfaces.Understanding the mechanism of immune regulation of M cells and dendritic cells and targeting them can be another promising approach for the successful stimulation of the mucosal immune system.This paper reviews the basic mechanisms of the mucosal immunity elicited by mucosal vaccines and summarizes the practical aspects and challenges of nanotechnology-based vaccine platform development,as well as ligand hybrid nanoparticles as potentially effective target delivery agents for mucosal vaccines.
基金supported by the National Natural Science Foundation of China(Nos.81872815,82030107,and 81690263)Science and Technology commission of Shanghai Municipality(No.19XD1400300,China)
文摘Orally administered drug entities have to survive the harsh gastrointestinal environment,penetrate the enteric epithelia and circumvent hepatic metabolism before reaching the systemic circulation.Whereas the gastrointestinal stability can be well maintained by taking proper measures,hepatic metabolism presents as a formidable barrier to drugs suffering from first-pass metabolism.The pharmaceutical academia and industries are seeking alternative pathways for drug transport to circumvent problems associated with the portal pathway.Intestinal lymphatic transport is emerging as a promising pathway to this end.In this review,we intend to provide an updated overview on the rationale,strategies,factors and applications involved in intestinal lymphatic transport.There are mainly two pathways for peroral lymphatic transportdthe chylomicron and the microfold cell pathways.The underlying mechanisms are being unraveled gradually and nowadays witness increasing research input and applications.
